Both compounds inhibited BTKY223 phosphorylation in PKCα-KR and primary CLL cells, causing a reduction in AKT/mTOR and ERK-MAPK/c-Myc mediated pathways. The gene discussed is MTOR; the disease is B-cell chronic lymphocytic leukemia.